These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1050 related articles for article (PubMed ID: 31994347)

  • 1. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.
    Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C
    Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma.
    Zhou M; Xu W; Yue X; Zhao H; Wang Z; Shi H; Cheng L; Sun J
    Oncotarget; 2016 May; 7(20):29720-38. PubMed ID: 27105492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
    Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
    J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A seven-long noncoding RNA signature predicts relapse in patients with early-stage lung adenocarcinoma.
    Zhou H; Zhang H; Chen J; Cao J; Liu L; Guo C; Huang G; Zeng D
    J Cell Biochem; 2019 Sep; 120(9):15730-15739. PubMed ID: 31050375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of prognostic biomarkers in lung adenocarcinoma based on aberrant lncRNA-miRNA-mRNA networks and Cox regression models.
    Yao Y; Zhang T; Qi L; Liu R; Liu G; Wang J; Song Q; Sun C
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31950990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel seven-long non-coding RNA signature predicts survival in early stage lung adenocarcinoma.
    Chen M; Liu B; Xiao J; Yang Y; Zhang Y
    Oncotarget; 2017 Feb; 8(9):14876-14886. PubMed ID: 28122330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel autophagy-related lncRNA survival model for lung adenocarcinoma.
    Wu L; Wen Z; Song Y; Wang L
    J Cell Mol Med; 2021 Jun; 25(12):5681-5690. PubMed ID: 33987935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA PCBP1-AS1 correlated with the functional states of cancer cells and inhibited lung adenocarcinoma metastasis by suppressing the EMT progression.
    Li Z; Pan C; Wang Z; Deng X; Zhu Q; Wu W; Chen L
    Carcinogenesis; 2021 Jul; 42(7):931-939. PubMed ID: 34107009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma.
    Peng F; Wang R; Zhang Y; Zhao Z; Zhou W; Chang Z; Liang H; Zhao W; Qi L; Guo Z; Gu Y
    Mol Cancer; 2017 Jun; 16(1):98. PubMed ID: 28587642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management.
    Ma X; Cheng J; Zhao P; Li L; Tao K; Chen H
    J Cell Mol Med; 2020 Jul; 24(13):7576-7589. PubMed ID: 32530136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
    Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
    World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.
    Ren J; Wang A; Liu J; Yuan Q
    Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Prognostic Biomarkers of Lung Adenocarcinoma Based on Bioinformatic Analysis.
    Hou J; Yao C
    Biomed Res Int; 2021; 2021():8859996. PubMed ID: 33511215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA Expression Signature in Prediction of the Prognosis of Lung Adenocarcinoma.
    Li L; Feng T; Qu J; Feng N; Wang Y; Ma RN; Li X; Zheng ZJ; Yu H; Qian B
    Genet Test Mol Biomarkers; 2018 Jan; 22(1):20-28. PubMed ID: 29297704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated analysis of long non-coding RNA‑associated ceRNA network reveals potential lncRNA biomarkers in human lung adenocarcinoma.
    Sui J; Li YH; Zhang YQ; Li CY; Shen X; Yao WZ; Peng H; Hong WW; Yin LH; Pu YP; Liang GY
    Int J Oncol; 2016 Nov; 49(5):2023-2036. PubMed ID: 27826625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers.
    Li R; Yang YE; Yin YH; Zhang MY; Li H; Qu YQ
    J Transl Med; 2019 Sep; 17(1):324. PubMed ID: 31558162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of an endoplasmic reticulum stress-associated lncRNA prognostic signature and the tumor-suppressive role of RP11-295G20.2 knockdown in lung adenocarcinoma.
    Yu L; Zhou S; Hong W; Lin N; Wang Q; Liang P
    Sci Rep; 2024 May; 14(1):12283. PubMed ID: 38811828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
    Zou X; Hu Z; Huang C; Chang J
    Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
    Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.